Ute Hegenbart

16.8k total citations · 1 hit paper
281 papers, 9.5k citations indexed

About

Ute Hegenbart is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Ute Hegenbart has authored 281 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Molecular Biology, 117 papers in Hematology and 63 papers in Oncology. Recurrent topics in Ute Hegenbart's work include Amyloidosis: Diagnosis, Treatment, Outcomes (160 papers), Multiple Myeloma Research and Treatments (56 papers) and Hematopoietic Stem Cell Transplantation (56 papers). Ute Hegenbart is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (160 papers), Multiple Myeloma Research and Treatments (56 papers) and Hematopoietic Stem Cell Transplantation (56 papers). Ute Hegenbart collaborates with scholars based in Germany, United States and Italy. Ute Hegenbart's co-authors include Stefan Schönland, Anthony D. Ho, Hartmut Goldschmidt, Giovanni Palladini, Giampaolo Merlini, Arnt V. Kristen, Christoph Kimmich, Christoph Röcken, Hugo A. Katus and Axel Benner and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Circulation.

In The Last Decade

Ute Hegenbart

262 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2012 625 citations Giovanni Palladini, Stefan Schönland et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ute Hegenbart Germany	51	5.8k	4.1k	2.1k	2.0k	1.3k	281	9.5k
Francis K. Buadi United States	57	8.7k 1.5×	7.8k 1.9×	4.8k 2.3×	2.3k 1.2×	1.1k 0.8×	398	12.5k
Paul J. Kurtin United States	64	3.3k 0.6×	1.5k 0.4×	3.6k 1.7×	2.8k 1.4×	930 0.7×	235	11.4k
Helen J. Lachmann United Kingdom	62	11.0k 1.9×	2.3k 0.6×	1.8k 0.8×	1.4k 0.7×	3.3k 2.6×	335	13.0k
Stefan Schönland Germany	43	5.9k 1.0×	1.5k 0.4×	1.5k 0.7×	1.6k 0.8×	1.4k 1.1×	222	7.2k
Javier de la Rubia Spain	42	2.5k 0.4×	4.9k 1.2×	2.4k 1.1×	1.1k 0.6×	610 0.5×	252	7.1k
Xavier Leleu France	53	6.4k 1.1×	6.9k 1.7×	4.4k 2.1×	3.0k 1.5×	236 0.2×	457	11.4k
Bruno Rotoli Italy	42	949 0.2×	2.3k 0.6×	1.2k 0.6×	1.1k 0.6×	323 0.3×	185	5.5k
Joan Bladé Spain	61	9.3k 1.6×	12.1k 3.0×	6.9k 3.2×	2.4k 1.2×	270 0.2×	324	14.8k
Donna Reece Canada	48	4.9k 0.9×	5.2k 1.3×	3.8k 1.8×	1.1k 0.6×	194 0.2×	349	8.2k
Ramón García‐Sánz Spain	53	4.0k 0.7×	5.5k 1.4×	3.7k 1.7×	3.1k 1.5×	180 0.1×	337	9.6k

Countries citing papers authored by Ute Hegenbart

Since Specialization

Citations

This map shows the geographic impact of Ute Hegenbart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Hegenbart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Hegenbart more than expected).

Fields of papers citing papers by Ute Hegenbart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ute Hegenbart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Hegenbart. The network helps show where Ute Hegenbart may publish in the future.

Co-authorship network of co-authors of Ute Hegenbart

This figure shows the co-authorship network connecting the top 25 collaborators of Ute Hegenbart. A scholar is included among the top collaborators of Ute Hegenbart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ute Hegenbart. Ute Hegenbart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hegenbart, Ute, Stefan Schönland, Jan Purrucker, et al.. (2024). T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy. Amyloid. 31(4). 309–317.

Stolz, Lukas, et al.. (2024). RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy. European Heart Journal. 45(Supplement_1).

Kühn, Lukas C., Christian Haupt, Sebastian Wiese, et al.. (2024). Cryo-EM structure of a lysozyme-derived amyloid fibril from hereditary amyloidosis. Nature Communications. 15(1). 9648–9648. 4 indexed citations

John, Lukas, Sandra Sauer, Ute Hegenbart, et al.. (2023). Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(10). 609.e1–609.e6. 4 indexed citations

Dittrich, Tobias, Martin Schorb, Niels Weinhold, et al.. (2023). High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders. Leukemia. 37(12). 2468–2478. 2 indexed citations

Poos, Alexandra M., Marc S. Raab, Hartmut Goldschmidt, et al.. (2023). Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma. FEBS Journal. 290(17). 4256–4267. 2 indexed citations

Granzow, Martin, et al.. (2022). Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. PLoS ONE. 17(2). e0264407–e0264407. 13 indexed citations

Radamaker, Lynn, Julian Baur, Matthias Neumann, et al.. (2021). Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. Nature Communications. 12(1). 6434–6434. 56 indexed citations

Ungerer, Matthias N., Ernst Hund, Jan Purrucker, et al.. (2020). Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid. 28(2). 91–99. 12 indexed citations

10.

Kimmich, Christoph, Tobias Terzer, Axel Benner, et al.. (2020). Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 135(18). 1517–1530. 61 indexed citations

11.

Kazman, Pamina, Benedikt Weber, Ute Hegenbart, et al.. (2020). Fatal amyloid formation in a patient’s antibody light chain is caused by a single point mutation. eLife. 9. 42 indexed citations

12.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2019). Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 104(11). 2274–2282. 23 indexed citations

13.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2017). HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS. Data Archiving and Networked Services (DANS). 1 indexed citations

14.

Middeke, Jan Moritz, Dietrich W. Beelen, Michael Stadler, et al.. (2012). Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−. Blood. 120(12). 2521–2528. 42 indexed citations

15.

Björkstrand, Bo, Simona Iacobelli, Ute Hegenbart, et al.. (2011). Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. Journal of Clinical Oncology. 29(22). 3016–3022. 118 indexed citations

16.

Meijer, Jiska, Stefan Schönland, Giovanni Palladini, et al.. (2008). Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. Arthritis & Rheumatism. 58(7). 1992–1999. 44 indexed citations

17.

Luft, Thomas, Michael Conzelmann, Axel Benner, et al.. (2007). Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 110(13). 4535–4542. 79 indexed citations

18.

Hegenbart, Ute, Dietger Niederwieser, Brenda M. Sandmaier, et al.. (2005). Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. Journal of Clinical Oncology. 24(3). 444–453. 181 indexed citations

19.

Sandmaier, Brenda M., David G. Maloney, Michael B. Maris, et al.. (2003). Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biology of Blood and Marrow Transplantation. 9(4). 266–272. 21 indexed citations

20.

Maloney, DG, Ted Gooley, Ute Hegenbart, et al.. (2001). NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: CLINICAL RESULTS OF A TBI-BASED CONDITIONING REGIMEN. Blood. 742–743. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact